AAOpt 2024: Eye care provider and patient satisfaction with lifitegrast

News
Video

Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.

Melissa Barnett, OD, FAAO, FSLS, discussed a real-world study on eye care professional and patient satisfaction with the dry eye treatment lifitegrast (Xiidra) at this year's American Academy of Optometry meeting. The study had a retrospective cross-sectional design and surveyed 12 eye care practitioners, including 6 ophthalmologists and 6 optometrists, about their experiences prescribing lifitegrast to an average of 1288 patients with dry eye disease. The key findings were:

  • On average, 21% of dry eye patients seen by ophthalmologists and 17% of those seen by optometrists were treated with lifitegrast.
  • Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, such as increased tear film breakup time, reduced corneal and conjunctival staining, and increased tear meniscus height.
  • Practitioners also reported moderate to high satisfaction with lifitegrast's ability to improve dry eye symptoms like itching, dryness, burning/stinging, redness, pain, light sensitivity, and blurred vision.
  • 58% of practitioners said at least one patient experienced mild to moderate adverse effects like blurred vision, burning/stinging, and dysgeusia (taste disturbance).
  • Overall, the majority of practitioners (over 50%) were either moderately or very satisfied with lifitegrast for treating their dry eye patients.

The key takeaways highlighted were the high prevalence of dry eye disease, the importance of evaluating and addressing dry eye in all patients, and the practical benefits of having an effective and well-tolerated treatment option like lifitegrast available. The study demonstrates that lifitegrast can provide meaningful improvements in both signs and symptoms of dry eye in real-world clinical practice.

Recent Videos
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
© 2025 MJH Life Sciences

All rights reserved.